Cyberattack Alert - Severe WARNINGS & CAUTIONS to All Members
NASDAQ 6,840.08 117.68 (+0.39%) DJIA 24,329.16 117.68 (+0.48%) S&P 500 2,651.50 14.52 (+0.55%) 08/12/2017 17:00

FDA


AstraZeneca's Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials

10/12/2017 23:45

Data from two Phase I/II trials presented at American Society of Hematology Annual Meeting...

New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients

10/12/2017 17:40

TAMPA, Fla. , Dec. 10, 2017 /PRNewswire/ -- A new article published today in The ...

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta(TM) (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma

10/12/2017 16:30

-- 42 Percent of Patients Remained in Response, Including 40 Percent in Complete Remission...

CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma

10/12/2017 16:30

ATLANTA , Dec. 10, 2017 /PRNewswire-USNewswire/ -- For people with certain types of ...

Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

10/12/2017 16:00

CAMBRIDGE, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical...

Page of 625

Terms and Conditions | Privacy Statement
Financial.org is an educational platform. We DO NOT deal with securities and receive any financial benefits from Financial Products & Service Providers.